Economy

Alnylam Pharmaceuticals, Inc. (ALNY) Stock Rating Reaffirmed by Stifel Nicolaus

The institutional investor owned 1,221,338 shares of the biopharmaceutical company's stock after selling 20,000 shares during the quarter.

Heading into the stock price potential, EdR needs to grow just 7.47% to cross its median price target of $41.

In the most updated research from a number of analysts on Wall Street, the company gets 11 Buys and 1 Sell among 18 analysts.

Shares of Alnylam Pharmaceuticals (NASDAQ:ALNY) opened at 112.92 on Wednesday.

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)'s earnings per share has been growing at a -28.7 percent rate over the past 5 year when average revenue increase was noted as -10.6 percent. Finally, Chardan Capital reiterated a "buy" rating and set a $131.00 target price (up previously from $110.00) on shares of Alnylam Pharmaceuticals in a report on Monday, July 10th. Morgan Stanley upped their price objective on Alnylam Pharmaceuticals from $46.00 to $50.00 and gave the company an equal weight rating in a research report on Thursday, August 10th. BidaskClub lowered Alnylam Pharmaceuticals from a "strong-buy" rating to a "buy" rating in a research note on Wednesday, August 16th. (NASDAQ:ALNY). This is based on a 1-5 scale where 1 indicates a Strong Buy and 5 a Strong Sell. The consensus analyst target price is $88.63.

Alnylam Pharmaceuticals (NASDAQ ALNY) traded up 3.450% during trading on Friday, hitting $116.816.

At the time of writing, the stock was trading at $1.69. Alnylam Pharmaceuticals, Inc. The firm has a 50-day moving average of $81.14 and a 200-day moving average of $69.12. Alnylam Pharmaceuticals has a 52-week low of $31.38 and a 52-week high of $118.40. The company has market cap of $10.54 billion. Alnylam Pharmaceuticals also was the target of some unusual options trading on Wednesday. After the recent moves, investors may also look to see if the stock has entered oversold or overbought territory and could be ripe for a bounce. This represents an increase of 937% compared to the average volume of 2,944 call options. The biopharmaceutical company reported ($1.34) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($1.22) by ($0.12). Alnylam Pharmaceuticals had a negative return on equity of 45.53% and a negative net margin of 670.81%. September 21 investment analysts at Leerink Swann kept the company rating at "Outperform" but raised the price expectation from $50.00 to $123.00. During the same period in the previous year, the business posted ($1.05) EPS. The company's revenue for the quarter was up 82.9% on a year-over-year basis. On average, equities research analysts predict that Alnylam Pharmaceuticals will post ($5.20) earnings per share for the current fiscal year.

TRADEMARK VIOLATION NOTICE: This story was published by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are accessing this report on another website, it was stolen and reposted in violation of USA and worldwide trademark & copyright legislation. FMR LLC grew its stake in Alnylam Pharmaceuticals by 6.3% in the 2nd quarter.

Investors are feeling more bullish on shares of the company of late if you watch the decrease in short interest. Wellington Management Group LLP grew its stake in Alnylam Pharmaceuticals by 0.3% in the 1st quarter. The Manufacturers Life Insurance Company increased its position in shares of Alnylam Pharmaceuticals by 7.0% during the second quarter. The Manufacturers Life Insurance Company now owns 2,541 shares of the biopharmaceutical company's stock valued at $203,000 after buying an additional 167 shares during the last quarter. BlackRock Inc. grew its stake in Alnylam Pharmaceuticals by 9.3% in the 2nd quarter. Manufacturers Life Ins The owns 2,541 shares or 0% of their U.S. portfolio. Finally, Baillie Gifford & Co. grew its stake in Alnylam Pharmaceuticals by 2.9% in the 2nd quarter. The short sellers then promise to replace the stock in the future and makes dividend payments out of their own pockets to cover the dividend income that is no longer exists on the original, now borrowed and sold, shares. The percentage of shares being held by the company management was 0.7% while institutional stake was 89.9%.



Like this

Latest


23 September 2017
Pakistan Violates Ceasefire in J&K's Keran Sector; Army Jawan Martyred
Kashmir, a Muslim-majority Himalayan region, is held by India and Pakistan in parts and claimed by both in full. Pakistan paramilitary troops befittingly responded on posts targeting civil population, the statement said.

23 September 2017
Boston Scientific Corp (NYSE:BSX) Institutional Investors Sentiment
Over the last five days, shares have faced -0.72% losses and now is up 12.3% since hitting its 200-day moving average of $26.61. The institutional investors in our partner's database now hold: 1.22 billion shares, down from 1.23 billion shares in 2017Q1.

23 September 2017
Boy, 17, arrested in connection with Parsons Green tube attack
A man in a red hat - carrying a Lidl bag - was also captured by cameras near the Jones's home about 90 minutes before the attack. A suicide bomber attacked a concert venue in Manchester in May, killing more than 20 people including children and mothers.

23 September 2017
Russian Federation says it will target US-backed fighters in Syria if provoked
Dillon added that the coalition and Russian officers shared maps and other data on where their forces were battling in the area. The U.S. air mission against the Islamic State is operating at a high tempo and making significant progress, Air Force Lt.

23 September 2017
Four-star SF Ignas Brazdeikis (2018) commits to MI basketball
Despite his size (6-8, 220 pounds), Brazdeikis will spend most of his time on the wing with the Wolverines . Brazdeikis is known on the AAU circuit for several 50-point outbursts, including two in March.

23 September 2017
NKorea bomb test would draw tough response
Tensions between North Korea and the United States have flared up again, with threats from both sides becoming alarmingly regular. Beijing has supported increasing United Nations sanctions but has objected to unilateral measures.

23 September 2017
Cowen and Company Lowers Versartis, Inc. (VSAR) to Market Perform
What Historical Figures Say About Versartis, Inc . (NASDAQ: VSAR ), with 4 analysts believing it is a strong buy. The stock of Versartis Inc (NASDAQ: VSAR ) has "Buy" rating given on Friday, September 8 by Piper Jaffray.

23 September 2017
Mauricio Pochettino: 'Trusting Eric Dier in midfield was a gamble'
But as a group, I think we wouldn't be happy unless we won something. That is the truth and I believe it and yesterday he told me that.

23 September 2017
Exelon Corporation (NYSE:EXC) EVP Sells $510787.23 in Stock
The Company, through its subsidiary, Exelon Generation Company, LLC (Generation), is involved in the energy generation business. Also, EVP Paymon Aliabadi sold 13,333 shares of the stock in a transaction that occurred on Monday, September 11th.

23 September 2017
Apple Watch fails to tick with reviewers due to cellular glitch
Gene Munster, a longtime Apple analyst with Loup Ventures, doubted issues with the Series 3 Watch would hurt Apple's bottom line. Apple said that the watch would have 18 hours of battery life, but it would sustain only for an hour for a cellular phone call.



Recommended